What Pergotime Treats: Main Uses and Benefits

Pergotime (clomifene) is utilized for the management of certain forms of infertility in women. The medicine is indicated for clinical scenarios where the difficulty in conceiving is linked to ovulatory dysfunction. Its primary role is to provide support in situations involving irregular or absent ovulation, assisting the processes intended to lead to the release of an egg. This therapy may be considered for individuals experiencing these specific challenges who wish to become pregnant.

Key therapeutic applications include sterility related to anovulation and oligo-ovulation (infrequent ovulation). It is also used as an aid in managing certain types of amenorrhea (absence of menstruation), such as those occurring after discontinuing oral contraceptives, provided other specific medical conditions are ruled out.

Quick Fact: Management for Ovulatory Issues Pergotime is designated to assist in the therapeutic management of ovulatory dysfunction, which is a factor in specific types of female infertility.

Eligibility Map: Who Can and Cannot Use Pergotime (Clomifene Citrate)

Pergotime's use is strictly defined by regulatory eligibility criteria documented in official government sources, primarily targeting adult women of reproductive age with established ovulatory dysfunction.

Use is absolutely contraindicated in several populations. These exclusions include pregnant women (Pregnancy Category X), patients with existing liver disease or a history of liver dysfunction, and individuals with abnormal uterine bleeding of undetermined origin. The medicine must also not be used by those with specific conditions such as ovarian cysts (not due to PCOS), uncontrolled thyroid or adrenal dysfunction, or hormone-dependent tumors.

Use is not established and therefore not indicated for pediatric or geriatric populations. Additionally, the label advises caution for patients with conditions like uterine fibroids and during lactation, as the medication may reduce milk supply. The official profile defines therapy as inefficient in cases of primary pituitary or primary ovarian failure.

Interactions with other medicines and products

This section describes interaction patterns for Pergotime (Clomifene citrate) based strictly on official regulatory documentation. Regulatory sources, including the FDA and the EMA, explicitly state that standard pharmacokinetic drug-drug interactions, such as those mediated by CYP enzymes, have generally not been documented or described.

---

Official Interaction Profile

Category	Documented Interaction or Restriction
Pharmacodynamic Risk	Concurrent use with Gonadotropins significantly increases the risk of Ovarian Hyperstimulation Syndrome (OHSS).
Administration Timing	Subsequent treatment with Progestins must not be administered before day 20 of the cycle as a required sequence rule.
Drug-Disease Prohibition	Use is formally prohibited (contraindicated) in individuals with existing liver disease or a history of liver dysfunction.
Population Note	Individuals with a pre-existing or family history of hyperlipidemia are associated with a documented risk of hypertriglyceridemia.

---

Interaction Summary

The interaction structure for Clomifene citrate is characterized by specific pharmacodynamic risks that must be managed, rather than widespread metabolic interferences. The primary constraints involve adherence to mandatory sequence-timing rules for other reproductive hormones and absolute prohibition for use in the presence of certain chronic conditions, as detailed in the official prescribing information.

How Pergotime Works

Pergotime (clomiphene citrate) acts by selectively modulating estrogen receptors in the central nervous system to initiate a hormonal cascade. The mechanism involves targeted interference within the hypothalamic-pituitary-ovarian (HPO) axis, specifically counteracting the natural hormonal negative feedback.

Modulating Central Estrogen Receptors

The drug binds to estrogen receptors in the hypothalamus, temporarily blocking natural estrogen from occupying these sites. This receptor blockade is interpreted by the brain as a state of low estrogen, which results in a compensatory signaling cascade within the central regulatory pathways.

Upregulating Gonadotropin Signaling

Following this central receptor event, the hypothalamus increases the pulsatile release of GnRH (Gonadotropin-Releasing Hormone). This subsequently stimulates the pituitary gland to release elevated levels of the gonadotropins, FSH (Follicle-Stimulating Hormone) and LH (Luteinizing Hormone), increasing the hormonal signaling for follicular recruitment.

Stimulating Ovarian Follicular Development

The surge of circulating FSH and LH acts directly on the ovaries, promoting the maturation of ovarian follicles and culminating in the induction of follicular rupture.

Administration Guidelines for Pergotime (Clomiphene Citrate)

Pergotime, containing Clomiphene Citrate, is administered orally as a tablet and should be used strictly according to the regimen prescribed by a specialist. The administration follows a cyclic protocol that is generally not continued for more than three total courses of treatment.

Administration Scope	Description
Route	Oral (by mouth)
Starting Day	On or about the fifth day of the menstrual cycle. If there is no recent spontaneous bleeding, treatment may be started at any time.
Initial Dosing	50 mg (one tablet) daily for 5 days.
Subsequent Dosing	If no ovulation occurs after the first course, a second course of 100 mg daily for 5 days may be given, starting at least 30 days after the prior course.
Timing	Take the tablet at approximately the same time each day during the 5-day course.
Missed Dose	If a dose is missed, contact your healthcare provider for instructions; do not take two doses at once to make up for a missed one.

It is essential to have a pelvic examination before beginning the first course and before each subsequent course to rule out pregnancy or ovarian enlargement. The physician determines the lowest dose consistent with the expectation of a favorable response. Long-term use is not recommended beyond approximately six total cycles.

Research Evidence / Overview of Studies

Phase II: Compound Activity and Safety Profile

Studies have sought to characterize the compound’s activity in relation to inflammatory signaling. Research has explored the potential relationship between the compound and specific patient outcomes, particularly those related to chronic pain.

Safety and Tolerability

Safety trials reported the distribution and nature of adverse events in adults. These studies found that the majority of reported events were mild and transient. Further long-term research is needed to fully characterize the safety profile.

---

Phase III: Evaluation in Pain Management

Research in Phase III trials focused on two primary areas: evaluating the compound when administered as a standalone treatment and examining its use as an adjunct therapy.

Primary Endpoint Evaluation

Large-scale, randomized controlled trials (RCTs) evaluated whether the compound was associated with a reduction in the inflammatory response in participants with condition X. While some trials showed a difference in the outcome measured, the findings regarding the magnitude of the measured endpoint were not uniform.

Combination Therapy Trials

This therapeutic approach involved administering the compound alongside standard care. One trial evaluated the time elapsed until a measurable change in the primary endpoint was observed, while others focused on the duration of symptoms. Research examined the sustained changes in participant symptom reports over a 12-week period.

Comparative studies were conducted to observe the measured endpoints in relation to treatments used for comparison.

---

Summary of Ongoing Research

Research is currently underway to further evaluate the long-term potential for this compound in wider patient populations. Interpretation of the clinical relevance of these findings requires a review of the full research data. The selection of individual treatments is a process conducted in consultation with a healthcare provider.

Key Studies & References

1. Non-Opioid Pramipexole Suppresses Immune NLRP3 Reactivity for Pain Control (Phase II/III Trial NCT03842709)
2. Promising Drug Candidate Reduces Inflammation, Chronic Pain in Mice (Preclinical Mechanistic Study)

Common questions about Pergotime (FAQ)

---

Q: What is the purpose of Pergotime (Clomifene)?

Pergotime, which contains the active substance clomifene, is used to help induce ovulation (the release of an egg) in women who are unable to become pregnant due to not ovulating. According to regulatory documents, it is typically used for women diagnosed with certain types of anovulatory infertility (infertility related to the lack of ovulation).

---

Q: How does Pergotime work to help with fertility?

The active ingredient in Pergotime, clomifene, works by mimicking the effect of estrogen on the body. This action stimulates the pituitary gland to release specific hormones that encourage the ovaries to produce and mature an ovarian follicle, which may lead to the release of an egg (ovulation). Official product information notes its purpose is to stimulate ovulatory function.

---

Q: Can Pergotime increase the chance of multiple births (twins or triplets)?

Yes, regulatory documents indicate that treatment with Pergotime carries an increased risk of multiple pregnancies, which includes twins and triplets. This possibility is due to the medicine stimulating the development of more than one egg. This is a known potential outcome that is mentioned in the official product information.

---

Q: What should I do if I miss a dose of Pergotime?

According to the official product information, if a dose is missed, it is recommended to contact your doctor immediately for guidance. Because the treatment involves a specific cycle of administration, your doctor will provide instruction on how to proceed, as timing is crucial for this treatment. Do not attempt to catch up by taking a double dose; consult your healthcare professional instead.

---

Q: Is Pergotime safe to use during a confirmed pregnancy?

No, Pergotime is contraindicated (should not be used) if a patient is already pregnant. Official warnings state that the medicine should not be administered to women with a confirmed or suspected pregnancy. For this reason, a pregnancy test is typically performed before treatment begins.

---

Q: Can Pergotime affect my vision?

Yes, visual symptoms are listed as a possible side effect of Pergotime in regulatory documents. These visual disturbances may include blurry vision, spots or flashes of light (scintillating scotomata), or sensitivity to light. If any changes in vision are noticed, official guidance suggests stopping the treatment and seeking medical consultation immediately.

---

Q: Is Pergotime only for women?

The primary and most frequent use of Pergotime is in the treatment of anovulatory infertility in women. However, regulatory sources also mention its potential use in treating certain cases of male infertility (e.g., oligospermia), where it may help stimulate sperm production. Any use in men must be determined by a healthcare professional.

The storage and disposal of Pergotime (clomifene citrate) must strictly follow official regulatory instructions to maintain product stability and ensure public safety.

Official Storage Conditions

Requirement	Specifics Mandated by Regulatory Labeling
Temperature	Store at Controlled Room Temperature (20 C to 25 C), with excursions allowed up to 30 C.
Protection	Keep in the original, tight, and light-resistant container. Protect from excessive heat and humidity.
Safety	Keep this and all drugs out of the sight and reach of children.

Official Disposal Rules

To prevent environmental contamination, do not dispose of unused or expired tablets by flushing them down a toilet or pouring them into a drain. Disposal must not occur with household waste.

Action: The medicine must be disposed of through a licensed pharmaceutical collection system. Patients are instructed to consult a pharmacist for the proper method to discard the product.